Harrow Posts 25c Q3 EPS, Swinging to Profit From Prior Loss
HROW is trading near its 52-week low of $25.76 (6.5% above the low).
Summary
Harrow reported third-quarter EPS of 25 cents, a sharp turn from the $17.3M net loss it posted in Q2, on revenue of $99.3M that slightly beat estimates on branded product growth. That Q2 loss came on revenue of $70.7M, up 60% sequentially on VEVYE and other branded products, so a positive EPS print implies the top line and cost base both moved the right way. Third-quarter gross margin was 75%. The quarter also includes the first contribution from TYRVAYA, which Harrow closed on October 5 under revised terms with Viatris retaining Japan rights. The company cut its full-year adjusted EBITDA outlook, which it had set above $40M.
At the time of this announcement, HROW was trading at $27.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $25.76 to $54.85. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.